NEW YORK (GenomeWeb News) – Nuclea Biotechnologies this week announced Immuno-Biological Laboratories will be the primary US distributor of Nuclea's HER-2/neu kits.

Nuclea and IBL also will coordinate joint marketing efforts for the serum HER-2/neu kits as part of the deal.

The microtiter-based test measures the level of HER-2/neu in serum and is used to monitor metastatic breast cancer. Based in Minneapolis, IBL distributes diagnostic assays for autoimmunity, endocrinology, infectious disease, oncology, and neuroscience. It also offers laboratory services.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The apple has traveled westward and eastward along the Silk Road, according to a new genetic analysis.

In Nature this week: GWAS data used to reposition drugs for psychiatric use, and more.

Genetic disease risk information doesn't always spur people to make healthy lifestyle changes, according to the Associated Press.

A University of California, San Diego-led team has used liquid biopsies to uncover possible treatments for patients with cancers of unknown primary.

Sep
20
Sponsored by
Ion Torrent

This webinar will discuss how next-generation sequencing (NGS) can help clinical research labs and pathologists save time, money, and samples compared to single-analyte oncology research assays.

Sep
21
Sponsored by
Roche

This webinar will demonstrate a new approach that combines precise FFPE tumor isolation with extraction-free DNA/RNA library preparation to minimize material losses and reduce the amount of tissue input required for NGS analysis.

Sep
27
Sponsored by
Philips Genomics

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.